|
US4284768A
(en)
*
|
1980-07-02 |
1981-08-18 |
American Home Products Corporation |
1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives
|
|
MY140679A
(en)
|
2001-05-24 |
2010-01-15 |
Avanir Pharmaceuticals |
Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
|
|
TW200418829A
(en)
*
|
2003-02-14 |
2004-10-01 |
Avanir Pharmaceutics |
Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
PL1879573T3
(pl)
|
2005-05-10 |
2013-05-31 |
Incyte Holdings Corp |
Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
CA2634198C
(en)
|
2005-12-20 |
2014-06-03 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
GB0605689D0
(en)
|
2006-03-21 |
2006-05-03 |
Novartis Ag |
Organic compounds
|
|
WO2007114239A1
(ja)
|
2006-03-30 |
2007-10-11 |
Sapporo Medical University |
DGKα阻害剤を含有する抗癌剤
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
ES2444574T3
(es)
|
2006-09-19 |
2014-02-25 |
Incyte Corporation |
N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
ES2776406T3
(es)
|
2007-07-12 |
2020-07-30 |
Gitr Inc |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
JP5583592B2
(ja)
|
2007-11-30 |
2014-09-03 |
ニューリンク ジェネティクス コーポレイション |
Ｉｄｏ阻害剤
|
|
US20110176972A1
(en)
|
2008-05-29 |
2011-07-21 |
Saint-Gobain Centre De Recherches et D'Etudes Eur |
Cellular structure containing aluminium titanate
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
EP2473531A4
(en)
|
2009-09-03 |
2013-05-01 |
Merck Sharp & Dohme |
Anti-gitr antibodies
|
|
US8722720B2
(en)
|
2009-10-28 |
2014-05-13 |
Newlink Genetics Corporation |
Imidazole derivatives as IDO inhibitors
|
|
PH12012500881A1
(en)
|
2009-12-10 |
2017-07-26 |
Hoffmann La Roche |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
JP5998060B2
(ja)
|
2010-03-04 |
2016-09-28 |
マクロジェニクス，インコーポレーテッド |
Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
|
|
CA2789076C
(en)
|
2010-03-05 |
2017-11-21 |
F. Hoffmann-La Roche Ag |
Antibodies against human colony stimulating factor-1 receptor and uses thereof
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
MX378336B
(es)
|
2010-05-04 |
2025-03-10 |
Five Prime Therapeutics Inc |
Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
|
|
PT2614082T
(pt)
|
2010-09-09 |
2018-12-03 |
Pfizer |
Moléculas de ligação a 4-1bb
|
|
NO2694640T3
(https=)
|
2011-04-15 |
2018-03-17 |
|
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
BR112014012624A2
(pt)
|
2011-12-15 |
2018-10-09 |
F Hoffmann-La Roche Ag |
anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
|
|
RU2014136332A
(ru)
|
2012-02-06 |
2016-03-27 |
Дженентек, Инк. |
Композиции и способы применения ингибиторов csf1r
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
EP2847220A1
(en)
|
2012-05-11 |
2015-03-18 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
JP6464139B2
(ja)
*
|
2013-03-14 |
2019-02-06 |
コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ |
ブロモドメイン含有タンパク質の阻害のための方法および組成物
|
|
CN112654621B
(zh)
*
|
2018-06-27 |
2024-05-14 |
百时美施贵宝公司 |
可作为t细胞活化剂的经取代萘啶酮化合物
|